On August 4, 2026 Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, reported Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 46th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026, at 12:30 p.m. ET in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Remix management team will also be hosting one-on-one meetings with investors. For those investors interested in scheduling a meeting, please contact your Canaccord representative.

(Press release, Remix Therapeutics, AUG 4, 2026, View Source [SID1234669689])